Jonas Sohlman appointed as new CEO for Intervacc
Stockholm, February 28, 2024 - The Board of Directors for Intervacc AB (publ) announces that acting CEO Jonas Sohlman has been appointed as the new CEO of Intervacc AB and assumes the position immediately.
The recruitment process that the previous board initiated has continued and now resulted in the appointment of Jonas Sohlman as the new CEO. Jonas has been working as the acting CEO since last August and assumes the role of CEO starting today.
“As the company finds itself in a crucial phase with many opportunities but also challenges, a well-informed and solution-oriented leader with an understanding of how Intervacc should develop to its full capacity is of utmost importance. Jonas has demonstrated over the past six months that he is well-suited to lead the company,” says Chairman of the board Håkan Björklund.
Jonas Sohlman has extensive experience from leadership positions in publicly listed companies. He most recently held the role of CFO at Enorama Pharma. Additionally, he has solid experience within the equestrian industry and currently serves as the chairman of both Flyinge AB and Ridskolan Strömsholm AB.
“I am both honored and pleased by the board’s trust in appointing me to lead Intervacc. Intervacc has an outstanding product and an exciting pipeline. I look forward to, together with my dedicated colleagues, spearheading the efforts to bring Strangvac® into a commercial phase and continuing our work on vaccine development projects. Our goal is to contribute to strengthening animal health and well-being.” says Jonas Sohlman.
For more information please contact:
Håkan Björklund, Chairman of the board
Phone: +46 (0)8 120 10 600
E-mail: [email protected]
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for immediate publication, through the agency of the contact person set out above on February 28, 2024.
About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: [email protected], Phone: +46 (0)8 – 684 211 10
